Figure. 4

Pharmacological modulation of REV-ERB inhibits HIV-1 replication in T cells and macrophages. (a) Jurkat cells were infected with VSV-G-pseudotyped HIV-1 NL4.3-Luc for 24 h. Infected cells were treated with SR9009 (20 µM) or SR8278 (20 µM) for 24 h and LTR activity measured (mean ± S.E.M., n = 3, One-way ANOVA). The IC₅₀ of SR9009 was determined at 24 h post treatment by quantifying luciferase activity. (b) Primary CD4 T cells were activated for 3 days with anti-CD3/CD28 and infected with VSV-G-pseudotyped HIV-1 NL4.3-Luc for 24 h and treated with SR9009 (20 µM) or SR8278 (10 µM) for 24 h and LTR activity measured (n = 4, mean ± S.E.M, One-way ANOVA). The IC₅₀ of SR9009 was determined at 24 h post treatment by quantifying luciferase activity. (c) Human induced pluripotent stem cells (iPSCs) derived macrophages were infected with VSV-G-pseudotyped HIV-1 NL4.3-Luc for 24 h and treated with SR9009 (10 µM) or SR8278 (5 µM) for 24 h and LTR activity measured (n = 3, mean ± S.E.M, One-way ANOVA). The IC₅₀ of SR9009 was determined at 24 h post treatment by quantifying luciferase activity. All data are expressed relative to the control untreated cells.